Clinical Trial Update: Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries [NA]

View source ↗

Summary

A completed clinical trial assessing fenretinide for preventing ovarian cancer in women at high risk (BRCA1/BRCA2 carriers) undergoing oophorectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Fenretinide (fenretinide)

Snippet

Sponsor: University of Arizona | Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier | NA | Status: COMPLETED